We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eagle Weighs Challenge Over FDA’s Rejection of Full Exclusivity
Eagle Weighs Challenge Over FDA’s Rejection of Full Exclusivity
Eagle Pharmaceuticals is objecting to the FDA’s decision to grant orphan drug Bendeka only three years of exclusivity instead of the full seven years and says it may take action.